ADRB2 and colorectal carcinoma: Some experimental studies show that suppression of β2AR but not β1AR signaling selectively suppresses CRC cell viability and inhibits CRC growth; however, others report that both β1 and β2 antagonists inhibit CRC growth14,20,21.